Mellozzan® (melatonin) approved in Turkey
11 september, 2025
Mellozzan® (melatonin) approved in Turkey
EQL Pharma's key product Mellozzan® (tablets) has been approved for sale by the Turkish Medicines Agency. EQL's partner in Turkey, Abdi Ibrahim, will both manufacture and market Mellozzan® locally. Sales are expected to commence in the first half of 2026.
EQL receives a single-digit royalty based on sales.
Mellozzan® in Turkey is expected to be expanded with the oral solution in 2027. The application is currently under review by the Turkish Medicines Agency. Abdi Ibrahim has also submitted an application for approval of Mellozzan® (tablets and oral solution) in Kazakhstan.
About Mellozzan®
Mellozzan® contains the sleep hormone melatonin and is indicated for children with ADHD and suffering from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan® is also indicated for the short-term treatment of jet lag in adults.
About Abdi Ibrahim
Abdi Ibrahim Pharmaceuticals is Turkey's largest pharmaceutical company with 5,500 employees.
EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 46 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.
For more information contact:
Axel Schörling,
CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com
Ämnen i artikeln
Mellozzan® (melatonin) approved in Turkey
11 september, 2025
Mellozzan® (melatonin) approved in Turkey
EQL Pharma's key product Mellozzan® (tablets) has been approved for sale by the Turkish Medicines Agency. EQL's partner in Turkey, Abdi Ibrahim, will both manufacture and market Mellozzan® locally. Sales are expected to commence in the first half of 2026.
EQL receives a single-digit royalty based on sales.
Mellozzan® in Turkey is expected to be expanded with the oral solution in 2027. The application is currently under review by the Turkish Medicines Agency. Abdi Ibrahim has also submitted an application for approval of Mellozzan® (tablets and oral solution) in Kazakhstan.
About Mellozzan®
Mellozzan® contains the sleep hormone melatonin and is indicated for children with ADHD and suffering from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan® is also indicated for the short-term treatment of jet lag in adults.
About Abdi Ibrahim
Abdi Ibrahim Pharmaceuticals is Turkey's largest pharmaceutical company with 5,500 employees.
EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 46 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.
For more information contact:
Axel Schörling,
CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com
Ämnen i artikeln
Analys
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
